Shots:
- The company has launched Guardant Reveal liquid biopsy test for the detection of residual and recurrent disease from a simple blood draw to monitor CRC patients with 7-day turnaround time, residual disease after surgery and recurrence mos. earlier than current SoC methods like CEA tests or imaging
- The test can deliver industry leading sensitivity of 91% for detecting ctDNA by simultaneously interrogating both genomic alterations and methylation. Additionally, it reports genomic alterations down to allele frequencies of 0.01%, and effectively filters out biological noise sources
- The Guardant Reveal test is company’s 1st commercially available liquid biopsy test for clinical use in the management of early-stage cancer which will focus first on early-stage CRC and later on additional cancer types
Click here to read full press release/ article | Ref: Guardant Health | Image: Guardant Health
The post Guardant Health Launches Guardant Reveal Liquid Biopsy Test for Early-Stage Colorectal Cancer first appeared on PharmaShots.